Clincosm LogoSign in Get a demo

Diagnostic and Evaluation of Hepato-pancreatico-biliary Disease With MRI

Sponsor
University of Zurich (Other)
Overall Status
Recruiting
CT.gov ID
NCT04701567
Collaborator
(none)
2,000
Enrollment
1
Location
42
Anticipated Duration (Months)
47.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a retrospective review of images from patient data. There is no recruitment necessary for this study.

Research Question: Can advanced multiparametric MRI techniques improve the detection and characterization of focal and diffuse liver disease, accurately assess treatment response and predict patient outcomes based on longitudinal monitoring? Hypotheses: Advanced multiparametric MRI techniques improve the detection, characterization and response assessment of focal and diffuse liver disease and can predict serious liver related outcomes.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Magnetic resonance imaging

Study Design

Study Type:
Observational
Anticipated Enrollment :
2000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Diagnostik Und Evaluierung Hepato-pankreatiko-biliärer Erkrankungen Mittels Morphologischer Und Funktioneller Magnetresonanztomographie
Actual Study Start Date :
Jun 30, 2020
Anticipated Primary Completion Date :
Dec 30, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Liver disease

Diagnostic Test: Magnetic resonance imaging
Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
Pancreatic disease

Diagnostic Test: Magnetic resonance imaging
Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease

Outcome Measures

Primary Outcome Measures

  1. Pathology findings in focal and/or diffuse liver disease [1 year]

    Pathology findings in focal and/or diffuse liver disease

  2. Pathology findings in focal and/or diffuse pancreatic disease [1 year]

    Pathology findings in focal and/or diffuse pancreatic disease

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:

  • Patients with suspicion for or diagnosed focal and/or diffuse liver or pancreatic disease who underwent MRI of the abdomen.

  • 18 years of age and older.

Exclusion Criteria:

  • Age less than 18 years.

  • Lack of MRI of the abdomen.

  • Inadequate image quality.

  • Documented rejection to participate in research studies

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Zurich Zurich Switzerland 8091

Sponsors and Collaborators

  • University of Zurich

Investigators

  • Principal Investigator: Caecilia Reiner, MD, University of Zurich

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Caecilia Reiner, Staff Radiologist, University of Zurich
ClinicalTrials.gov Identifier:
NCT04701567
Other Study ID Numbers:
  • BASEC ID 2020-01313
First Posted:
Jan 8, 2021
Last Update Posted:
Jan 8, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Liver Diseases
Pancreatic Diseases

Study Results

No Results Posted as of Jan 8, 2021